An independent two-stage DCF analysis by a frontier AI model.
Incyte's valuation hinges on its ability to transition its revenue base away from its legacy blockbuster, Jakafi, before exclusivity is lost. The company has made significant strides with Opzelura and a maturing pipeline, yet the market remains cautious about the long-term growth trajectory.
Our intrinsic value model suggests the current market price fairly reflects the base-case scenario of stable near-term cash flows and moderate pipeline success. Significant upside would require unexpected outperformance from the early-stage pipeline or accretive business development to fully replace expiring revenue streams.
We project an 8% free cash flow growth rate over the next five years. This balances the strong current top-line growth with the eventual impact of generic competition on mature products.
A 9% discount rate is applied, reflecting the inherent clinical and regulatory risks associated with the biotechnology sector, offset by Incyte's established commercial profitability.
A conservative 2% terminal growth rate assumes the company will eventually mature and grow slightly below the broader economy, accounting for the continuous cycle of patent cliffs.
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 1.0% | $81.47 | $69.83 | $61.10 | $54.31 | $48.88 |
| 1.5% | $88.87 | $75.20 | $65.17 | $57.51 | $51.45 |
| 2.0% | $97.76 | $81.47 | $69.83 | $61.10 | $54.31 |
| 2.5% | $108.62 | $88.87 | $75.20 | $65.17 | $57.51 |
| 3.0% | $122.20 | $97.76 | $81.47 | $69.83 | $61.10 |
■ Undervalued vs current price ■ Overvalued vs current price
The 8% rate reflects a blend of high near-term growth from recent product launches and the longer-term drag from eventual patent expirations on older therapies.
The primary risk is a failure of late-stage pipeline assets to materialize, leaving the company heavily exposed to revenue declines when key patents expire.
The 9% discount rate is relatively high compared to non-healthcare sectors, heavily discounting future cash flows to account for the binary risks of drug development and regulatory approval.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.